XML 66 R56.htm IDEA: XBRL DOCUMENT v3.22.2.2
Significant transactions and events (Details)
9 Months Ended
Jun. 08, 2022
EUR (€)
D
€ / shares
Sep. 30, 2022
EUR (€)
Option
payment
Milestone
tranche
€ / shares
shares
Jul. 01, 2022
EUR (€)
Significant transactions and events      
First portion of total consideration transferred, amount   € 1,560,000  
Issuance and transfer of shares to former Frame shareholders | shares   810,242  
Value of shares issued to former Frame shareholders   € 11,040,000  
Value of shares issued to former Frame shareholders   € 7,198,000  
Shares transferred | shares   858,496  
Closing Share Price | € / shares   € 13.63  
Issuance and transfer of shares as consideration for discharging the contractual obligations for the outstanding advisory agreements | shares   48,254  
Value of shares issued as consideration for discharging the contractual obligations for the outstanding advisory agreements   € 657,000  
Strike price for existing share-based payment   767,000  
Cash payments   585,000  
Consideration paid in cash for the settlement of the vested employee options   335,000  
Additional cash consideration   € 250,000  
Contingent consideration, Percentage of total consideration   50.00%  
Contingent consideration, Number of milestones | Milestone   2  
Number of shares issued upon the achievement of the successful investigational new drug application filing | shares   194,647  
Percentage of consideration transferred upon the achievement of the successful investigational new drug application filing   10.00%  
Value of shares issued upon the achievement of the successful investigational new drug application filing   € 32,000,000.0  
Number of shares issued upon successful proof of mechanism in humans | shares   778,589  
Percentage of consideration transferred upon successful proof of mechanism in humans   40.00%  
Value of shares issued upon successful proof of mechanism in humans   € 32,000,000.0  
Contingent consideration, fair value   19,481,000  
Value of aggregate consideration in shares   € 7,198,000  
Contingent Consideration, Maximum shares issuable | shares   973,236  
RSUs issued to certain former employees | Option   89,655  
Total fair value of the RSU grant   € 1,218,000  
Number of tranches for vesting of RSUs granted | tranche   3  
Transactions costs   € 500,000  
Provisional fair value   6,216,000  
Amount of fair value   11,697,000  
Signing share price representing 10%   1,831,000  
Signing share price representing 40%   5,367,000  
Closing share price representing total fair value   7,198,000  
Frame Pharmaceuticals B.v.Amsterdam Netherlands      
Significant transactions and events      
Revenues contributed to the consolidated result   0  
Loss contributed to the consolidated result   600,000  
Loss of combined entity as if combination occurred at beginning of period   3,000,000.0  
Total purchase price € 32,000,000.0 € 19,481,000  
Net amount of discharging contractual obligations € 1,560,000    
Signing Share Price, Number of trading days considered | D 60    
Signing Share Price | € / shares € 16.44    
Number of payments in which the total consideration is to be paid | payment   3  
Contingent consideration, Number of payments considered | payment   2  
First portion of total consideration transferred, percentage     50.00%
First portion of total consideration transferred, amount     € 16,000,000.0
Value of shares issued as consideration for discharging the contractual obligations for the outstanding advisory agreements   € 1,560,000  
Cash payments   € 585,000